{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:42:06Z","timestamp":1772160126685,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study evaluated the effectiveness and safety of switching the basal insulin (BI) in a BI\u2010supported oral therapy (BOT) to insulin glargine 300\u2009U\/ml (Gla\u2010300) in adults with inadequately controlled type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This was a non\u2010interventional, multicentre, prospective 12\u2010month study, conducted in Germany, Austria and Switzerland. The study documented people with T2D with glycated haemoglobin (HbA1c) between 7.5% and 10.0%, currently treated by a non\u2010Gla\u2010300 BOT regimen, after the physician had decided to switch the BI to Gla\u2010300. Primary endpoint was the proportion of patients achieving the fasting plasma glucose (FPG; \u2264110\u2009mg\/dl) target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 1194 participants comprised the full analysis set, of which 793 completed documentation of 12\u2009months Gla\u2010300 treatment (FAS\u2010M12). The main previous BI was insulin glargine 100\u2009U\/ml (Gla\u2010100; 47.2%). Twelve months after switching to Gla\u2010300, 27.0% of FAS\u2010M12 participants achieved the FPG target and 44.8% their individualized HbA1c target. The greatest FPG target achievements were seen in previous Gla\u2010100 (29.3%), and greatest HbA1c target achievements in previous insulin detemir users (57.7%). The mean FPG decreased by \u221236.3\u2009\u00b1\u200951.2\u00a0mg\/dl to 135.5\u2009\u00b1\u200936.9\u00a0mg\/dl and mean HbA1c by \u22120.79\u2009\u00b1\u20091.01% to 7.45\u2009\u00b1\u20090.94%. Symptomatic and nocturnal hypoglycaemia incidence significantly decreased over 12\u2009months of Gla\u2010300 treatment. Body weight remained unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching the BI to Gla\u2010300 in a BOT regimen improved metabolic control and treatment satisfaction in a substantial proportion of patients with T2D and inadequate target achievement within 12\u2009months in clinical practice with a decreased risk of symptomatic and nocturnal hypoglycaemia and without weight gain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14549","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T03:31:01Z","timestamp":1631503861000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Switching the basal insulin to insulin glargine 300\u2009U\/\n                    <scp>ml<\/scp>\n                    in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-7310","authenticated-orcid":false,"given":"Jochen","family":"Seufert","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center, University of Freiburg, Faculty of Medicine University of Freiburg  Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4711-6946","authenticated-orcid":false,"given":"Peter","family":"Wiesli","sequence":"additional","affiliation":[{"name":"Hospital for Internal Medicine Kantonsspital Frauenfeld  Frauenfeld Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-1961","authenticated-orcid":false,"given":"Andreas","family":"Fritsche","sequence":"additional","affiliation":[{"name":"Hospital for Internal Medicine IV University of Tuebingen  Tuebingen Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich University of Tuebingen (IDM)  Tuebingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Anderten","sequence":"additional","affiliation":[{"name":"Joint Practice Anderten\u2010Krok &amp; Partner  Hildesheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-5305","authenticated-orcid":false,"given":"Katrin","family":"Pegelow","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Deutschland GmbH  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Pscherer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III Sophien\u2010 and Hufeland\u2010Hospital  Weimar Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-0302","authenticated-orcid":false,"given":"Martin","family":"Pfohl","sequence":"additional","affiliation":[{"name":"Medical Clinic I Evang. Bethesda\u2010Hospital Duisburg  Duisburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2019"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"issue":"1","key":"e_1_2_9_5_1","first-page":"S65","article-title":"Praxisempfehlungen der Deutschen Diabetes Gesellschaft. Therapie des Typ\u20102\u2010Diabetes","volume":"15","author":"Landgraf R","year":"2020","journal-title":"Diabetologie"},{"key":"e_1_2_9_6_1","unstructured":"LehmannR GastaldiG CzockA EgliM Fischer\u2010TaeschlerD LaimerM LucchiniB ThalmannS WiesliP.Empfehlungen der Schweizerischen Gesellschaft f\u00fcr Endokrinologie und Diabetologie (SGED\/SSED) f\u00fcr die Behandlung von Diabetes mellitus Typ 2 (2020) 28 February 2020. .https:\/\/www.sgedssed.ch\/fileadmin\/user_upload\/6_Diabetologie\/61_Empfehlungen_Facharzt\/2020_Swiss_Recomm_Medis_DE_def.pdf"},{"key":"e_1_2_9_7_1","unstructured":"\u00d6sterreichische Diabetes Gesellschaft (Gast\u2010Hrg.).Diabetes mellitus \u2013 Anleitungen f\u00fcr die Praxis. \u00dcberarbeitete und erweiterte Fassung 2019. Wien Klin Wochenschr (2019).131 [Suppl 1]:S1\u2013S245. Diabetes\u2010mellitus\u2010Anleitungen\u2010fuer\u2010die\u2010Praxis\u20102019.PDF (oedg.at)"},{"key":"e_1_2_9_8_1","unstructured":"\u00d6sterreichische Diabetes Gesellschaft.Antihyperglyk\u00e4mische Therapie bei Diabetes mellitus Typ 2 \u2013 Update J\u00e4nner 2021.https:\/\/www.oedg.at\/pdf\/2021-01-Update-Antihyperglykaemische-Therapie-bei-Diabetes-mellitus-Typ-2.pdf"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.970633"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0651-3"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13199"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12532"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14264"},{"key":"e_1_2_9_15_1","volume-title":"Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice","author":"Bradley C","year":"1994"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1708287"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00734-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13697"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13345"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000548"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0568-8"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2019.04.012"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00902-1"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01436-5"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13952"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13535"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01383-w"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14265"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13818"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000409"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejsp.401"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14549","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:19:57Z","timestamp":1761891597000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/dom.14549"],"URL":"https:\/\/doi.org\/10.1111\/dom.14549","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14549\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14549\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14549\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14549\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14549\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14549\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"2021-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}